This company has been marked as potentially delisted and may not be actively trading. Aptose Biosciences (APTO) Stock Forecast & Price Target Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsEarningsFDA EventsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock Get the Latest News and Ratings for APTO and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Aptose Biosciences and its competitors. Enter your email to sign up for newsletter Sign Up APTO Analyst Ratings Over TimeTypeCurrent Forecast7/17/24 to 7/17/251 Month Ago6/17/24 to 6/17/253 Months Ago4/18/24 to 4/18/251 Year Ago7/18/23 to 7/17/24Strong Buy1 Strong Buy rating(s)1 Strong Buy rating(s)1 Strong Buy rating(s)0 Strong Buy rating(s)Buy1 Buy rating(s)1 Buy rating(s)2 Buy rating(s)6 Buy rating(s)Hold0 Hold rating(s)0 Hold rating(s)0 Hold rating(s)0 Hold rating(s)Sell0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)Consensus Price Target$6.00$6.00$93.00$445.00Forecasted UpsideN/A250.88% Upside5,338.60% Upside2,130.58% UpsideConsensus RatingStrong BuyStrong BuyBuyBuy APTO Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History APTO Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Aptose Biosciences Stock vs. The CompetitionTypeAptose BiosciencesMedical CompaniesS&P 500Consensus Rating Score 3.50 2.81 2.53Consensus RatingStrong BuyModerate BuyModerate BuyPredicted UpsideN/A8,763.35% Upside11.26% UpsideNews Sentiment RatingNeutral NewsSee Recent APTO NewsPositive NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export to Excel DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails3/28/2025HC Wainwright1 of 5 starsJoseph PantginisSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost TargetBuy ➝ Buy$2.00 ➝ $6.00+80.18%2/27/2025Alliance Global Partners1 of 5 starsM. VeneziaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/16/2024Canaccord Genuity Group2 of 5 stars Lower TargetBuy ➝ Buy$450.00 ➝ $180.00+396.65%4/3/2024Piper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy rating Reiterated RatingOverweight ➝ Overweight$150.00+233.18%11/10/2023Royal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy rating Lower TargetOutperform ➝ Outperform$690.00 ➝ $540.00+564.21%9/7/2023Cantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy rating Reiterated RatingOverweight ➝ Overweight$1,140.00+913.33%8/11/2023OppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy rating Lower TargetOutperform ➝ Outperform$1,500.00 ➝ $450.00+275.00%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 05:06 PM ET. APTO Forecast - Frequently Asked Questions What is Aptose Biosciences' forecast for 2025? According to the research reports of 2 Wall Street equities research analysts, the average twelve-month stock price forecast for Aptose Biosciences is $6.00, with a high forecast of $6.00 and a low forecast of $6.00. Should I buy or sell Aptose Biosciences stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aptose Biosciences in the last twelve months. There is currently 1 buy rating and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "strong buy" APTO shares. Does Aptose Biosciences's stock price have much upside? According to analysts, Aptose Biosciences's stock has a predicted upside of ∞ based on their 12-month stock forecasts. Do Wall Street analysts like Aptose Biosciences more than its competitors? Analysts like Aptose Biosciences more than other "medical" companies. The consensus rating for Aptose Biosciences is Strong Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how APTO compares to other companies. Stock Forecasts and Research Tools Related Companies AIM ImmunoTech Stock Forecast Prime Medicine Stock Forecast Inhibikase Therapeutics Stock Forecast Protalix BioTherapeutics Stock Forecast bluebird bio Stock Forecast HOOKIPA Pharma Stock Forecast Neuphoria Therapeutics Stock Forecast MetaVia Stock Forecast Briacell Therap Stock Forecast Leap Therapeutics Stock Forecast Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter This page (NASDAQ:APTO) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptose Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aptose Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
